“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.

See omnystudio.com/listener for privacy information.

“Forty percent of patients in this country alone in the first year drop out [of current retinal disease treatments] and every one of those patients ends up going blind. By far the most expensive disease in the world is blindness and the reason for that is really quite simple. It’s because the mortality doesn’t change, the use of resources skyrockets, but the mortality doesn’t change. In this country, every blind patient costs over $66,000 a year,” says Pravin Dugel, CEO of Ocular Therapeutix. “If we reduce that dropout rate by even 10% with Axpaxli, and I’m sure we’ll do even better, we’re talking about a quarter million fewer patients in this country alone who will not go blind. The impact of that, not just on a human basis but on an economic basis, is astronomical.” In this episode of the Vanguards of Healthcare podcast, Pravin sits down with Bloomberg Intelligence senior analyst Ann-Hunter van Kirk to discuss how the company can reduce the therapeutic and economic burden of retinal diseases.

See omnystudio.com/listener for privacy information.

“This deal [with Eli Lilly, announced on Sunday 29 March] is a combination of an asset licensing and collaboration. We’ve collaborated with Lilly in the past and they are actually one of the most active and expert users of our software,” says Alex Zhavoronkov, founder and co-CEO of Insilico Medicine. Zhavoronkov joins Bloomberg Intelligence pharmaceuticals analyst Sam Fazeli to explain how Insilico is using AI to compress drug-discovery timelines from years to months, pursue novel targets and compete with both big pharma and China’s fastest-moving biotech players. They also discuss the company’s rapid Lilly deal and why AI’s real edge may be before the clinic, not inside it.

See omnystudio.com/listener for privacy information.

EDAP can treat prostate cancer by focusing ultrasound waves at just the target region, similar to how a magnify glass can focus light from the sun so intensely that it can burn a piece of paper, allowing it to eliminate the cancer while limiting side effects, CEO Ryan Rhodes explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Rhodes sits down with BI analyst Matt Henriksson to talk about his path from Intuitive Surgical to lead EDAP, how the Focal One robot uses high intensity focused ultrasound, or HIFU, to ablate prostate cancer without needing an incision or removing the whole prostate and how the HIFI Study shows that Focal One can be a viable alternative to radical prostatectomy.

See omnystudio.com/listener for privacy information.

Haemonetics, a medical-device maker that focuses on markets including blood and plasma collection, is evolving to expand broadly with more diversification and greater sustainability over time, all with the view that good products win, CEO Chris Simon explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simon sits down with BI analyst Matt Henriksson to talk about Haemonetics and how its has built out its hospital franchise with M&A to include high-growth segments that diversifies the company beyond its traditional blood and plasma collection businesses. He also shares his views on how medtech companies need to have products with competitive advantages as the hospital environment rationalizes and whittles down the number of medtech suppliers they use.

See omnystudio.com/listener for privacy information.

OrthoPediatrics’ aspiration is to develop anatomically appropriate implants, instruments and specialized braces for children, so surgeons don’t need to “MacGyver” their way with treating a child with adult sized devices, CEO David Bailey explains to Bloomberg Intelligence, referring to the multi-skilled character from the 1980s TV series. In this Vanguards of Health Care podcast episode, Bailey sits down with BI analyst Matt Henriksson for an in-depth interview to talk about OrthoPediatrics, how its technology built a cohesive commercial model to aid pediatric orthopedic surgeons, including products and clinical support, and how it has developed a strong M&A platform to add innovation to its portfolio.

See omnystudio.com/listener for privacy information.

“We’re staking the company on personalization: If you can make the health-care experience more personal to the individual, they’ll be more likely to engage around their health care and take the proper actions to get better outcomes,” Chris Michalak, CEO of Personify Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Michalak joins BI analyst Jonathan Palmer to discuss the merger of Virgin Pulse and HealthComp, the company’s AI-driven personalization engine and the value proposition for employers. The conversation also covers Personify’s approach to consolidation in health care, the role of navigation and the impact of GLP-1 drugs on the market.

See omnystudio.com/listener for privacy information.

Bolt Navigation has shrunk the use of a navigation system for spine surgery into an Apple iOS device, using the gyroscope-on-chip technology to make spinal fusion cases more accurate in any surgery setting, CEO Patrick West says. In this episode of Bloomberg Intelligence’s Vanguards of Health Care podcast, West sits down with BI analyst Matt Henriksson to talk about how the Bolt Navigation Unit leverages the gyroscope and an X-ray acquired once the patient is positioned for pedicle screw placement, with no special imaging required during the procedure. West goes on to say how this technology can penetrate ambulatory surgical centers, that can perform simple spinal fusion cases without a robot they may not be able to afford

See omnystudio.com/listener for privacy information.

Modern medicine hasn’t made big strides in managing psychiatric disorders, a growing challenge with global implications. “The treatment of psychiatric disorders hasn’t changed from what it was like 30 years ago, medications are given by trial and error and we don’t really know what’s going to work,” Amit Etkin, CEO of Alto Neuroscience, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. BI senior health-care associate Jean Rivera Irizarry joins Dr. Etkin for an in-depth interview about Alto, how it was formed, its drug-selection process and how the company aims to redefine the way we treat such disorders.

See omnystudio.com/listener for privacy information.

Vericel acquired a hidden gem in cartilage repair that other companies had written off, and developed it into a high-growth product that could potentially address a $4 billion market. In this episode of the Vanguards of Health Care podcast, Vericel CEO Nick Colangelo sits down with Matt Henriksson, Bloomberg Intelligence analyst, to talk about how MACI took over as the market leader for cartilage repair in the knee and its potential to do so for the ankle. Colangelo also discusses why the company built a diversified portfolio and how NexoBrid complements its Epicel platform to fill out the company’s burn-care offerings.

See omnystudio.com/listener for privacy information.

Dr. Stephen Hoge, Moderna’s head of R&D, joined the Vanguards of Health Care podcast to share his insights on the company’s groundbreaking work in messenger RNA. In this episode, Dr. Hoge and Bloomberg Intelligence’s Sam Fazeli take listeners into an in-depth conversation on how Covid was just the start of using mRNA as a way of treating disease. They also discuss Moderna’s cancer trials and its approach to rare diseases. 

See omnystudio.com/listener for privacy information.

“We’re here to lower the cost of prescription drugs for every American,” Mark Thierer, CEO of Waltz Health explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Thierer joins BI senior health care analyst Jonathan Palmer to discuss Waltz’s Marketplace Search solutions for pharmacies and payers and why the upcoming launch of its Intelligent Specialty Engine is a game changer. He also shares his insights into the latest trends affecting the PBM industry.

See omnystudio.com/listener for privacy information.

“We are driving the market to exome and genome testing with a goal of making multigene panels be a thing of the past” Katherine Stueland, CEO of GeneDx, tells Bloomberg Intelligence’s analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast. They discuss GeneDx’s 80% market share in exome sequencing, the evolution of the genetic testing market and why the company’s core mission is delivering clinically-actionable results in rare diseases.  

See omnystudio.com/listener for privacy information.

“I think 2026 is the year of fundamental, agentic transformation of the workflow.” Abridge co-founder and CTO Zack Lipton joins Bloomberg Intelligence analyst Jonathan Palmer to share how the company grew from a research-heavy idea into one of health care’s breakout AI leaders. Lipton breaks down the limits of point solutions, the complexity of evaluating generative AI in medicine, and why he sees the future not as a better digital scribe alone, but as a unified platform that can guide documentation, billing and care decisions in real time.

See omnystudio.com/listener for privacy information.

Penumbra keeps a two-page list of key thrombectomy opportunities and technologies to innovate that allows it to keep transforming, presently with its computed-assisted vacuum technology (CAVT) for removing clots from the body, CEO Adam Elsesser explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Elsesser sits down with BI analyst Matt Henriksson for an in-depth interview about Penumbra, how CAVT can sense the pressure differentials between clot and blood to suck clot when it’s there and close the valve when not in order to limit blood loss, and how a serendipitous lunch was enough for him to adapt and expand technology originally designed for neuro cases to also treat peripheral disease, which has become Penumbra’s largest and fastest-growing segment.

See omnystudio.com/listener for privacy information.

Dexcom is expanding its portfolio of continuous glucose monitors (CGMs) with the launch of Stelo, balancing the needs of patients and payors to maximize the use of the technology, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down with BI analyst Matt Henriksson for an in-depth interview about how G7, Dexcom’s flagship CGM, is capturing share in every market it’s in, how the launch of Stelo opens up CGM access to nearly 25 million Type 2 diabetes patients in the US and how any patient can order the new CGM without a prescription.

See omnystudio.com/listener for privacy information.

Enovis is well positioned in the orthopedic market, combining small-cap focus on product innovation with large-cap functionality, CEO Matt Trerotola tells Bloomberg Intelligence. That includes its commercial team, balance sheet and M&A, which let it penetrate some of the fastest-growing segments. In this Vanguards of Health Care podcast episode, Trerotola sits down with BI analyst Matt Henriksson for an in-depth interview about Enovis, how its technology has gained an edge in shoulders and ankles, how its focus on ambulatory surgical centers has created a niche in knees and hips and how it has honed its M&A prowess to continually add new innovation to its portfolio.

See omnystudio.com/listener for privacy information.

When Wegovy was approved in 2021, patients began inquiring about whether Ro could build a product that would give them the “Ro experience” in weight loss: The company went to work at the end of 2021, spent all of 2022 building it, launched in 2023 and is now scaling up, CEO and co-founder Zachariah Reitano explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Reitano sat down with BI analyst Jonathan Palmer to discuss how the Ro platform is uniquely positioned to scale in chronic care, the drivers of unprecedented demand for GLP-1 drugs, how taking friction out of the patient experience led to early success and why he’s trying to recreate his physician father with technology.

See omnystudio.com/listener for privacy information.

Butterfly Network looks to streamline the ultrasound workflow and disrupt the incumbent market with its portable ultrasound technology that uses semiconductors instead of traditional crystals, CEO Joe DeVivo explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, DeVivo sits down with BI analyst Matt Henriksson to talk about Butterfly’s new iQ3 system that employs computer chips from TSMC (Taiwan Semiconductor Manufacturing Co.) to match the quality of traditional ultrasound, all in the palm of a physician’s hand. This has the potential to streamline ultrasound appointments as a point-of-care option that allows immediate scans and diagnostics.

See omnystudio.com/listener for privacy information.

“People who engage with an Included clinician experienced an average of two additional healthy days per month,” Owen Tripp, CEO of Included Health, explains to Bloomberg Intelligence. Tripp joins BI analyst Jonathan Palmer for this episode of the Vanguards of Health Care podcast for a wide-ranging discussion on why “healthy days” are Included’s North Star, the evolution of navigation and why over 30% of the Fortune 500 has contracted with the company. The conversation also covers Included’s progress in leveraging its care-delivery franchise, work around identifying quality and how member-centric product design improves outcomes while creating value.

See omnystudio.com/listener for privacy information.

CathWorks has developed a mapping platform for coronary arteries that streamlines cases, with a subscription model that can potentially accelerate its adoption and transition doctors away from traditional catheters, CEO Ramin Mousavi explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Mousavi sits down with BI analyst Matt Henriksson to talk about CathWorks, how the FFRangio technology takes a routine angiogram exam, or X-ray, and its in-house AI algorithm to create a 3D map of the arteries. He also discusses how the FastFFR clinical trial showed that using fractional flow reserve measurements has a 93% diagnostic accuracy, and the next steps in implementing a Netflix-style commercial model through its partnership with Medtronic.

See omnystudio.com/listener for privacy information.

“We started this company looking at the current genomics field and evaluating the gap we’re trying to fill,” Molly He, CEO and co-founder of Element Biosciences, explains to Bloomberg Intelligence. Dr. He joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the intricacies of building a new gene-sequencing instrument from scratch, the challenges of getting customers to adopt technology from new entrants and why the extension of the AVITI system beyond DNA into protein and cellular analysis is so important.

See omnystudio.com/listener for privacy information.

IRhythm Technologies’ Zio ambulatory cardiac monitors have the potential to change how doctors screen for irregular heartbeats by combining miniaturized biosensors and AI data analytics into a patch, CEO Quentin Blackford explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Blackford sits down with BI analyst Matt Henriksson for an in-depth interview on iRhythm, how its Zio platform technology, powered by its second-generation AI network, allows patients to be monitored without disrupting their everyday lives and how the recent Camelot trial data shows Zio to be more accurate and less costly to the health-care system than traditional monitors.

See omnystudio.com/listener for privacy information.

Caira Surgical is innovating radar technology to make it precise enough for use in navigating surgeons through knee-replacement procedures, where every millimeter matters for an accurate outcome, co-founders Jon Greenwald and Mort Meftah explain to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Greenwald and Meftah sit down with BI analyst Matt Henriksson for an in-depth interview about Caira, how sub-millimeter radar technology can be an improvement over traditional optical tracking for orthopedic surgery and the potential path to expand navigation and robotic capabilities within ambulatory surgical centers.

See omnystudio.com/listener for privacy information.

“In health care, in order to drive the biggest impact, the biggest outcomes and the biggest exits, you really have to engage the end consumer,” says Alyssa Jaffee, partner at 7Wire Ventures. In this Vanguards of Health Care episode, Jaffee sits down with Bloomberg Intelligence analyst Jonathan Palmer to discuss 7Wire’s thesis-driven approach to venture investing, how the firm works shoulder to shoulder with founders and why health care still offers endless opportunities to fix broken systems. She also reflects on women’s health, the evolving AI landscape and the personal values — integrity, work ethic and mission — that shape how she invests and leads.

See omnystudio.com/listener for privacy information.

Insulet is disrupting how patients can treat their diabetes, capitalizing on its differentiated Omnipod on-the-body delivery technology, CEO Jim Hollingshead explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Hollingshead sits down with BI analyst Matt Henriksson for an in-depth interview on Insulet’s Omnipod patch pump technology, how on-the-body wear compares with traditional insulin pumps and opens access to patients still using syringes, and upcoming developments to expand its automated insulin-delivery technology to Type 2 diabetic patients.

See omnystudio.com/listener for privacy information.

Johnson & Johnson has multiple robotic development projects that are set to expand its market-leading position in advanced surgical technology, Hani Abouhalka, company group chairman, Robotics & Digital, Johnson & Johnson Medtech, explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Abouhalka sits down with BI analyst Matt Henriksson to talk about developments in J&J’s multiple robotic platforms, including the Monarch system for bronchoscopy and urological procedures and the Ottava system designed for general surgery; and how J&J’s Ethicon presence helps drive a differentiated experience for surgeons.

See omnystudio.com/listener for privacy information.

Stereotaxis is developing robotic capabilities to enhance procedures for treating atrial fibrillation, with several innovations in the works. In this Vanguards of Health Care podcast episode, CEO David Fischel sits down with Bloomberg Intelligence analyst Matt Henriksson for a discussion about how the company’s Robotic Navigation System helps patients and future prospects for the use of robotics in cardiology surgery. 

See omnystudio.com/listener for privacy information.

Amputation is never a desired outcome. That’s why Podimetrics is working on innovations, as well as public awareness, around early detection of diabetic ulcers to prevent unnecessary procedures, co-founder and CEO Jon Bloom explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Jon sits down with BI analyst Matt Henriksson for an in-depth interview about Podimetrics, the state of diabetic ulcers and why current guidelines may be waiting until it is too late for patients with diabetic foot complications. He also reflects on how his experience as an anesthesiologist paved the way to develop the SmartMat as an in-home touchpoint for these patients.

See omnystudio.com/listener for privacy information.

"This decade will be defined by the affordability crisis and our vision as a company is to solve the affordability crisis in US healthcare," apree health CEO Donald Trigg explains to Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Trigg joins BI senior health care analyst Jonathan Palmer for a deep dive into apree's advanced primary care and digital engagement capabilities, how the combination of Vera Whole Health and Castlight positions the company to bring a differentiated solution set to help employers as well as health plans improve outcomes while lowering costs, and its progress in proving out its thesis across distinct market models. 

See omnystudio.com/listener for privacy information.

Eddii is driving its diabetes-management technology around the concept that patients require emotional support as much as a glucose reading, cofounder Farhaneh Ahmadi explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Farhaneh sits down with BI analyst Matt Henriksson for an in-depth interview about the company, its diabetes-management app and its partnership with Dexcom that provides further benefit with continuous glucose monitors. Eddii’s initial launch in middle America, where some patients are hundreds of miles away from the nearest endocrinologist, is also discussed.

See omnystudio.com/listener for privacy information.

“It was pretty clear as we looked at pharmacy-cost trends that where we were and where we were trying to go was just unsustainable,” Paul Markovich, CEO of Blue Shield of California explains to Bloomberg Intelligence. Markovich joins BI analyst Jonathan Palmer on this Vanguards of Health Care podcast episode to discuss the details of the company’s new prescription model, why it’s walking away from traditional pharmacy-benefit managers arrangements and how the insurer is going to generate $500 million in savings on over $4 billion in annual drug spending. Blue Shield’s work-around digital innovation, value-based care and the potential of GLP-1 drugs are also highlighted.

See omnystudio.com/listener for privacy information.

"We're the only ones in navigation that engage directly with all providers to use health signals from both members and providers to create next best steps," Quantum Health's CEO Zane Burke explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Burke joins BI analyst Jonathan Palmer to discuss the burgeoning need for health-care navigation and advocacy in a deep dive on Quantum's capabilities and how they improve clinical outcomes while generating a positive return on investment for clients. He also touches on a recent benefits survey that showed 60% of consultants recommend navigation for their clients and how Quantum's member engagement figures were the catalyst for joining the company. 

See omnystudio.com/listener for privacy information.

Onward Medical is driving the path to help paraplegics with spinal cord injuries regain their lives, CEO Dave Marver explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Marver sits down with BI analyst Matt Henriksson for an in-depth interview about the company, recent developments in its ARC therapy that bridges brainwaves to bypass damaged nerves and the ability for neuromodulation to restore movement and provide other potential benefits, including improved bladder control, blood pressure regulation and sexual function.

See omnystudio.com/listener for privacy information.

CVRx’s baroreflex activation therapy (BAT) technology can potentially treat heart failure for millions of patients without taking up precious real estate within the heart, CEO Nadim Yared explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Nadim sits down with BI analyst Matt Henriksson for an in-depth interview about the company, including recent developments in BAT and how its Barostim NEO, an implantable pulse generator, works for heart-failure patients even though it’s placed away from the organ.

See omnystudio.com/listener for privacy information.

“Nothing excites me as much as the potential for AI,” Xaira CEO Marc Tessier-Lavigne tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. They explore how artificial intelligence could cut drug development timelines in half and triple clinical success rates. Tessier-Lavigne, a former Genentech R&D leader, explains why today’s 13-year, 90% failure model is broken and how causal cell models, generative protein design and smarter patient stratification can transform target selection, drug creation and trials. Tessier-Lavigne also details why Xaira is chasing “high-hanging fruit,” the hard-to-drug targets others can’t reach, and what it will take to reverse Eroom’s Law.

See omnystudio.com/listener for privacy information.

Vektor Medical has developed the vMap system that can detect and locate arrhythmias in the heart with just a traditional ECG scan, potentially changing how doctors map out cardiac ablations in the future, CEO Rob Krummen explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Rob Krummen sits down with BI analyst Matt Henriksson for an in-depth interview about the company, how vMap uses proprietary algorithms to generate 3D cardiac maps and the future of technology use in cardiac ablations and pacing.

See omnystudio.com/listener for privacy information.

“We’ve come in with an offering that’s broader and deeper than a lot of data aggregators, but on top of that we’ve built really simple software that allows people in a no-code sort of way to just ask questions that they can get answers to instantly, and that’s why we’re winning,” Komodo Health cofounder and CEO Arif Nathoo explains. In this episode of the Vanguards of Health Care podcast, Nathoo sits down with Bloomberg Intelligence analyst Jonathan Palmer for a detailed discussion on the origins of Komodo’s data and analytics platform, the nuances that differentiate it for enterprise customers and the power of its longitudinal Healthcare Map database.

See omnystudio.com/listener for privacy information.

Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains. In this episode of the Vanguards of Health Care podcast, Connelly joins Bloomberg Intelligence biotech analyst Marc Engelsgjerd for a discussion of Elicio’s novel, lymph node-targeting vaccine platform, the company’s recent transition to the public markets via a reverse merger and the biotech scene in Boston’s booming Seaport district, where Elicio is based.  

See omnystudio.com/listener for privacy information.

Tandem Diabetes Care is developing several new insulin pumps to offer patients choices, starting with the Mobi miniaturized one, which was recently approved by the FDA, CEO John Sheridan explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview on Tandem’s product pipeline, the upcoming launch of Mobi, including the temporary disruption in 2H as patients wait for the product, and the importance of a mentor to build the right culture.

See omnystudio.com/listener for privacy information.

Asensus Surgical has several developments as it plans to develop augmented intelligence capabilities to work in tandem with the next generation of robotic surgery, CEO Anthony Fernando and CFO Shameze Rampertab explain to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Fernando and Rampertab sit down with BI analyst Matt Henriksson for an in-depth discussion about the company and recent developments in robotic surgery, including its next-generation Luna system and enhancements to its Intelligent Surgical Unit (ISU).

See omnystudio.com/listener for privacy information.

The 20-30% where a provider is actually making a clinical decision is what makes or breaks the outcome but the problem is that 100% of that work is manually driven, Memora Health cofounder and CEO Manav Sevak explains. In this episode of the Vanguards of Health Care podcast, Sevak joins BI analyst Jonathan Palmer for a deep dive into how Memora helps optimize care delivery and the patient experience against a backdrop where providers and payors are searching for alignment in complex businesses. 

See omnystudio.com/listener for privacy information.

Women and families are underserved in the health-care system, with almost 40% of US counties lacking an obstetrics-gynecologist, Maven Clinic founder and CEO Kate Ryder explains to Bloomberg Intelligence analyst Jonathan Palmer in this episode of the Vanguards of Health Care podcast. Ryder speaks in depth about unmet needs as the driver behind building the world’s largest virtual clinic for women and family health with a platform that covers 15 million lives spanning fertility, pregnancy, pediatrics and menopause. She highlights the challenges facing employers after the Dobbs decision, how international growth is exploding and why learning to be resilient is key. 

See omnystudio.com/listener for privacy information.

Color Health is delivering care programs in the public and private sectors that vertically integrate disparate workflows to drive outcomes for all stakeholders, cofounder and CEO Othman Laraki tells Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Laraki sits down with BI analyst Jonathan Palmer for a discussion on the company’s pivot to health delivery, the challenges facing self-insured employers, its partnership with the American Cancer Society and why fee-for-service shouldn’t be a dirty word. 

See omnystudio.com/listener for privacy information.

Impulse Dynamics has innovated cardiac contractility modulation (CCM) technology to relieve the symptoms for millions of heart failure patients, CEO Simos Kedikoglou explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Simos sits down with BI analyst Matt Henriksson for an in-depth interview on Impulse Dynamics, recent developments in CCM, and the future of combining CCM with traditional defibrillator technology to create a two-for-one heart failure treatment device.

See omnystudio.com/listener for privacy information.

Vicarious Surgical aims to disrupt the surgical robotic market by streamlining its robotic system to provide the necessary tools for a range of medical procedures, all within a single incision that is less than two centimeters, Cofounder and CEO Adam Sachs explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sachs sits down with BI analyst Matt Henriksson for an in-depth interview to discuss recent developments in robotic surgery, the company’s upcoming US launch and the Hollywood classic film Fantastic Voyage.

See omnystudio.com/listener for privacy information.

“IVL in general is an enabler for physicians to do very complex procedures — it’s simple, it’s easy to use and it’s safe. So even a physician that doesn’t have a lot of experience doing complex cases can now treat patients that they previously weren’t treating,” AVS Pulse Chairman Mark Toland tells Bloomberg Intelligence, referring to calcified arterial lesions in peripheral artery disease. In this Vanguards of Health Care episode, Toland joins BI analyst Matt Henriksson to discuss how the Pulse intravascular lithotripsy (IVL) system is differentiated vs. current technology, aiming to make treatment more flexible. He also highlights clinical results from the POWER PAD II pivotal trial, the commercial strategy ahead of FDA approval, and the expanding opportunity as aging demographics drive more hardened lesions that require IVL.

See omnystudio.com/listener for privacy information.

Dexcom’s continuous glucose monitor (CGM) technology is transforming how patients measure their sugar levels by simplifying their diabetes management, CEO Kevin Sayer explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Sayer sits down with BI analyst Matt Henriksson for an in-depth interview to talk about the company, its new G7 launch, expanded reimbursement coverage and marketing with recording artist, songwriter and Type 1 diabetes patient Nick Jonas.

See omnystudio.com/listener for privacy information.

 GoodRx is a marketplace, sort of like the Switzerland of health care, working with all constituents on behalf of the customer, co-founder and co-CEO Doug Hirsch explains to Bloomberg Intelligence. In this episode of the Vanguards of Health Care podcast, Hirsch sits down with BI analyst Jonathan Palmer to talk about GoodRx’s evolving business model, the power of its brand and why he’s not worried about structural changes to the market for prescription drugs. 

See omnystudio.com/listener for privacy information.

Trancarent’s at-risk care model enables consumers to reach a physician in less than 60 second with solutions spanning everyday care to pharmacy, home and specialty, CEO and Founder Glen Tullman explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, BI analyst Jonathan Palmer talks with Tullman and explores the health care challenges facing self-insured employers, the shifting landscape of primary care and the benefits of Transcarent’s acquisition of 98point6’s virtual care platform. 

See omnystudio.com/listener for privacy information.